MMI 0100

(HB3813)

Certificate of Analysis

Latest Certificate of Analysis

Download the latest CoA for this product:

Download CoA

Download Batch-Specific CoA

To download the CoA for a batch, enter the batch ID below:

Technical documents: CoA Datasheet

Product overview

Name MMI 0100
Purity >95%
Description

MAPKAPK2 (MK2) inhibitor. Cell permeable.

Write Your Own Review
You're reviewing:MMI 0100
Rate this item:

Biological Data

Biological description

Cell permeable MAPKAPK2 (MK2) inhibitor which targets the MK2 substrate-binding site. Shown to ameliorate memory deficit induced by Aβ1-42 or lipopolysaccharide in novel object and location tasks. Reduces cardiac and pulmonary fibrosis and ammeliorates lung inflammation. Also attenuates DSS-induced body weight loss, colon length shortening, and colonic pathological injury in DSS induced models of acute colitis.

Solubility & Handling

Solubility overview Soluble in PBS (1 mg/ml), and in DMSO
Storage instructions -20°C
Storage of solutions Prepare and use solutions on the same day if possible. Store solutions at -20°C for up to one month if storage is required. Equilibrate to RT and ensure the solution is precipitate free before use.
Shipping Conditions Stable for ambient temperature shipping. Follow storage instructions on receipt.
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Calculators

Molarity

=
x
x
More Info

Dilution

x
=
x
More Info

Chemical Data

Purity >95%
Molecular Weight 2283.64
Molecular Formula C98H171N37O26
CAS Number 1039342-24-9

References for MMI 0100

References are publications that support the biological activity of the product
  • Intranasal MMI-0100 Attenuates Aβ(1-42)- and LPS-Induced Neuroinflammation and Memory Impairments via the MK2 Signaling Pathway.

    Jiang J et al (2019) Frontiers in immunology 10 : 2707
  • MMI-0100 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice through Targeting MK2 Pathway.

    Wang Z et al (2019) Molecules (Basel, Switzerland) 24 :
  • MMI-0100 Inhibits Cardiac Fibrosis in a Mouse Model Overexpressing Cardiac Myosin Binding Protein C.

    Meng Q et al (2017) Journal of the American Heart Association 6 :
  • MMI-0100 inhibits cardiac fibrosis in myocardial infarction by direct actions on cardiomyocytes and fibroblasts via MK2 inhibition.

    Xu L et al (2014) Journal of molecular and cellular cardiology 77 : 86-101
  • Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce.

    Ward B et al (2009) Journal of peptide science : an official publication of the European Peptide Society 15 : 668-74

5 Item(s)